First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib

NCT01289821 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Neoplasms

Interventions

DRUG: Regorafenib (Stivarga, BAY73-4506)
DRUG: Oxaliplatin
DRUG: Folinic acid
DRUG: 5-FU (mFOLFOX6)

Sponsor

Bayer